Internist, Hematology Specialist, Oncology Specialist (cancer)
17 years of experience

Accepting new patients
Hematology Oncology Assoc
175 Madison Ave
Mount Holly, NJ 08060
609-267-0700
Locations and availability (1)

Education ?

Medical School
University Of Cape Town (1993)
Foreign school

Awards & Distinctions ?

Associations
American Society of Hematology
American Board of Internal Medicine

Affiliations ?

Dr. Wallace is affiliated with 7 hospitals.

Hospital Affilations

Score

Rankings

  • Virtua Memorial Hospital Of Burlington County
    Medical Oncology
    175 Madison Ave, Mount Holly, NJ 08060
    • Currently 2 of 4 crosses
  • Virtua West Jersey Hospital - Marlton
    Medical Oncology
    94 Brick Rd, Marlton, NJ 08053
    • Currently 2 of 4 crosses
  • Virtua West Jersey Hospital - Voorhees
    94 Brick Rd, Marlton, NJ 08053
    • Currently 2 of 4 crosses
  • Virtua West Jersey Health System-Voorh
  • St Barnabas Medical Center
  • Fox Chase Cancer Center
  • Fox Chase Virtua CancerProgram
  • Publications & Research

    Dr. Wallace has contributed to 1 publication.
    Title Factors Associated with Toxicity and Response to Yttrium 90-labeled Ibritumomab Tiuxetan in Patients with Indolent Non-hodgkin's Lymphoma.
    Date February 2005
    Journal Clinical Lymphoma
    Excerpt

    Treatment of patients with indolent non-Hodgkin's lymphoma (NHL) is evolving. These patients usually present with advanced-stage disease. Treatment options for patients who experience relapse are limited, and no treatment has been shown to be superior to others in improving overall survival of this group of patients, with the possible exception of allogeneic stem cell transplantation. Therefore, new approaches are needed to improve outcomes in patients with relapsed or refractory disease. The anti-CD20 monoclonal antibody, rituximab, was the first monoclonal antibody approved for the treatment of indolent B-cell NHL. As a single agent in the treatment of relapsed or refractory indolent lymphoma, response rates as high as 56% have been observed. This promising new therapy was followed by development of radioimmunotherapy, a novel treatment approach that combines the targeting capability of monoclonal antibodies with the additional cytotoxic effects of radiation. Yttrium 90-labeled ibritumomab tiuxetan (Zevalin) is a radiolabeled monoclonal antibody that has been shown to produce clinically significant responses in up to 80% of patients with indolent NHL and is the first radiolabeled monoclonal antibody approved for therapeutic use in the treatment of lymphoma. This article reviews some of the safety and efficacy data for this agent in addition to examining factors that could aid in predicting response and toxicity in patients with low-grade relapsed or refractory NHL treated with 90Y ibritumomab tiuxetan.

    Similar doctors nearby

    Dr. Maurice Cairoli

    Internal Medicine
    26 years experience
    Mount Holly, NJ

    Dr. Jyothi Jagadeesh

    Internal Medicine
    16 years experience
    Mount Holly, NJ

    Dr. Praveen Gollapudi

    Anesthesiology
    11 years experience
    Mount Holly, NJ

    Dr. Jeffrey Morris

    Emergency Medicine
    33 years experience
    Mount Holly, NJ

    Dr. Kia Pratt-McCoy

    Internal Medicine
    9 years experience
    Mount Holly, NJ

    Dr. Zaheer Husain

    Internal Medicine
    12 years experience
    Mount Holly, NJ
    Search All Similar Doctors